<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818103</url>
  </required_header>
  <id_info>
    <org_study_id>2007027</org_study_id>
    <secondary_id>2007027</secondary_id>
    <nct_id>NCT00818103</nct_id>
  </id_info>
  <brief_title>Characteristic Study on Chinese Patients With Multiple Sclerosis</brief_title>
  <official_title>Characteristic Study on Chinese Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <brief_summary>
    <textblock>
      Compared with MS in white populations, in people of China descent multiple sclerosis (MS)is
      characterized by lower prevalence, more frequent and severe involvement of the visual system
      at onset and during the entire clinical course, more common occurrence of optic and spinal
      involvement, relatively rapid progression and less common occurrence of a progressive course.
      Data are not available for mainland China that are focused on characteristic studies of MS.
      In this study, the investigators sought to explore the characteristics of MS among Chinese in
      China, by conducting a study on genetics, pathogenesis, pathology, neuroimaging
      characteristics, and so on. Based on these data, the investigators try to explore the
      difference in neuromyelitis optical (NMO) and MS and provide clinical data for treatment
      guidelines for NNO and MS.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence of NMO or MS</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EDSS scores, active lesion detected by MRI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Atorvastatin, β-interferon, EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Atorvastatin 40mg p.o. qn for 2 years</description>
    <arm_group_label>Atorvastatin, β-interferon, EPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>β-interferon</intervention_name>
    <description>β-interferon 50ug i.m. qod for 2 years</description>
    <arm_group_label>Atorvastatin, β-interferon, EPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO</intervention_name>
    <description>EPO 10000U i.h. bid for 5 days</description>
    <arm_group_label>Atorvastatin, β-interferon, EPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Criteria for neuromyelitis optical

               -  Optic neuritis

               -  Acute myelitis

          -  At least two of three supportive criteria:

               -  Contiguous spinal cord MRI lesion extending over &gt;= 3 vertebral segments

               -  Brain MRI not meeting diagnostic criteria for multiple sclerosis

               -  NMO-IgG seropositive status

          -  Criteria for multiple sclerosis:

               -  Two or more attacks; objective clinical evidence of two or more lesions, OR

               -  Two or more attacks; objective clinical evidence of one lesion, dissemination in
                  space, demonstrated by: MRI or two or more MRI-detected lesions consistent with
                  MS plus positive CSF or wait further clinical attack implicating a different
                  site, OR

               -  One attack; objective clinical evidence of two or more lesions, dissemination in
                  time, demonstrated by: MRI or second clinical attack, OR

               -  One attack; objective clinical evidence of one lesion (monosymptomatic
                  presentation; clinically isolated syndrome), dissemination in space, demonstrated
                  by: MRI or two or more MRI-detected lesions consistent with MS plus positive CSF
                  and dissemination in time, demonstrated by: MRI or second clinical attack, OR

               -  Insidious neurological progression suggestive of MS, one year of disease
                  progression (retrospectively or prospectively determined) and two of the
                  following:

                    1. Positive brain MRI (nine T2 lesions or four or more T2 lesions with positive
                       VEP)

                    2. Positive spinal cord MRI (two focal T2 lesions)

                    3. Positive CSF

        Exclusion Criteria:

          -  &gt; 65 yrs old

          -  Heavy damage of heart, lung, liver, renal function

          -  Late neuromyelitis optical or EDSS &gt; 6.0

          -  Serious hypertension and diabetes

          -  Serious mental disorders and depression

          -  Allergic to drug: atorvastatin, β-interferon, EPO, immunoglobulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiang Xue Hu, PhD</last_name>
    <phone>+862085252336</phone>
    <email>huxueqiangzssy@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Zheng Lu, PhD</last_name>
    <phone>+862085252336</phone>
    <email>lzq1828@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, The Third Affilated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Xue Hu, PhD</last_name>
      <phone>+862085252336</phone>
      <email>huxueqiangzssy@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19300400?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum</url>
  </link>
  <results_reference>
    <citation>Zhang B, Jiang Y, Yang Y, Peng F, Hu X. Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett. 2008 Apr;29(2):256-60.</citation>
    <PMID>18404143</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>September 27, 2009</last_update_submitted>
  <last_update_submitted_qc>September 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Hu Xueqiang</name_title>
    <organization>The Third Affiliated Hospital of Sun Yat-sen University, Department of Neurology</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis,Genetics,Pathogenesis,Pathology,Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

